The FDA has approved pembrolizumab (Keytruda) for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection (CR).
Regulatory
FDA approves adjuvant Keytruda for certain adults, children with stage IIB, IIC melanoma
The FDA approved pembrolizumab as adjuvant therapy for adults and children aged 12 years or older with stage IIB or IIC melanoma after complete resection.
FDA Orphan Drug Designation Granted to ST101 for Advanced Cutaneous Melanomas
The FDA granted a fast track designation to ST101 for the treatment of advanced cutaneous melanoma in patients who have disease progression on or after anti-PD-1/anti-PD-L1 therapy.
NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma
The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund.